Associated Genetic Biomarkers
NCI Definition: A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis. The majority are renal cell carcinomas. Kidney carcinomas usually affect middle aged and elderly adults. Hematuria, abdominal pain, and a palpable mass are common symptoms. 
Kidney carcinomas most frequently harbor alterations in VHL, PBRM1, SETD2, TP53, and BAP1 .
VHL Mutation, PBRM1fs, SETD2 Mutation, PBRM1 Mutation, and TP53 Mutation are the most common alterations in kidney carcinoma .
There are 8 clinical trials for kidney carcinoma, of which 6 are open and 2 are completed or closed. Of the trials that contain kidney carcinoma as an inclusion criterion, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open).
EGFR, KRAS, and NTRK1 are the most frequent gene inclusion criteria for kidney carcinoma clinical trials .
Pembrolizumab, abbv-321, and afm24 are the most common interventions in kidney carcinoma clinical trials.
Significant Genes in Kidney Carcinoma
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.